Abbott Laboratories Company Insiders

ABT Stock  USD 107.59  0.52  0.49%   
Slightly above 82 percent of Abbott Laboratories' insiders are selling. The analysis of insiders' sentiment of trading Abbott Laboratories stock suggests that a fairly large number of insiders are terrified at this time. Abbott Laboratories employs about 114 K people. The company is managed by 64 executives with a total tenure of roughly 504 years, averaging almost 7.0 years of service per executive, having 1781.25 employees per reported executive.
Robert Ford  CEO
President, Chief Executive Officer, Chief Operating Officer, Director
Miles White  Chairman
Chairman, CEO and Chairman of Executive Committee

Abbott Laboratories' Insider Buying Vs Selling

18

 
Selling
 
Buying

Latest Trades

2024-03-01Daniel Gesua Sive SalvadoriDisposed 963 @ 118.5View
2024-02-23Andrea F WainerDisposed 12500 @ 120View
2024-01-29Andrea F WainerDisposed 42500 @ 112.5View
2024-01-23Kathy E. ManningDisposed @ 114
2024-01-17Thomas R. CarperDisposed @ 113.96
2023-12-14Andrea F WainerDisposed 15000 @ 108View
2023-12-04John R. CurtisDisposed @ 105.19
2023-10-26Daniel J StarksDisposed 50000 @ 94.05View
2023-10-24Greg StantonDisposed @ 94.81
2023-10-03Markwayne MullinAcquired @ 95.79
2023-09-26Greg StantonAcquired @ 96.22
2023-09-21Pete RickettsDisposed @ 98.93
2023-09-13John R. CurtisAcquired @ 102.71
2023-08-08Andrea F WainerDisposed 10400 @ 105.03View
2023-07-27Daniel J StarksDisposed 50000 @ 113.76View
2023-05-02Daniel J StarksDisposed 50000 @ 111.02View
Monitoring Abbott Laboratories' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Abbott Laboratories' insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Abbott Laboratories. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Abbott Laboratories' stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy Abbott Stock please use our How to Invest in Abbott Laboratories guide.

Abbott Laboratories' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Abbott Laboratories' future performance. Based on our forecasts, it is anticipated that Abbott will maintain a workforce of slightly above 114000 employees by May 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Abbott Laboratories' latest congressional trading

Congressional trading in companies like Abbott Laboratories, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Abbott Laboratories by those in governmental positions are based on the same information available to the general public.
2023-12-04Representative John CurtisDisposed Under $15KVerify
2023-09-26Representative Greg StantonAcquired Under $15KVerify
2023-09-21Senator John P RickettsAcquired $100K to $250KVerify
2022-10-17Senator Thomas R. CarperAcquired Under $15KVerify
2021-10-28Representative Kim SchrierDisposed Under $15KVerify
2021-03-04Representative Carol Devine MillerAcquired Under $15KVerify
2021-02-16Representative Peter MeijerDisposed $15K to $50KVerify
2021-01-05Representative Dean PhillipsAcquired Under $15KVerify
2020-11-05Representative Katherine M. ClarkDisposed Under $15KVerify
2020-09-28Representative K. Michael ConawayAcquired $15K to $50KVerify
2020-04-07Senator Kelly LoefflerAcquired Under $15KVerify
2020-03-18Representative Gilbert CisnerosAcquired Under $15KVerify
2020-03-03Senator Shelley Moore CapitoAcquired Under $15KVerify
2019-09-12Representative Richard W. AllenAcquired $15K to $50KVerify
2019-04-09Senator Tina SmithAcquired $250K to $500KVerify
2018-11-05Representative Thomas J. RooneyAcquired $15K to $50KVerify
2018-04-05Senator Shelley M CapitoAcquired Under $15KVerify
2017-10-24Senator Bill CassidyAcquired Under $15KVerify
2017-10-18Senator Tammy DuckworthAcquired Under $15KVerify
2017-02-23Senator Sheldon WhitehouseAcquired Under $15KVerify

Abbott Laboratories Management Team Effectiveness

The company has Return on Asset of 0.0611 % which means that on every $100 spent on assets, it made $0.0611 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1511 %, implying that it generated $0.1511 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024.
Net Income Applicable To Common Shares is likely to gain to about 8.4 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 1.3 B in 2024.

Abbott Laboratories Workforce Comparison

Abbott Laboratories is number one stock in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 120,890. Abbott Laboratories totals roughly 114,000 in number of employees claiming about 94% of equities under Health Care industry.

Abbott Laboratories Profit Margins

The company has Net Profit Margin of 0.14 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.14 %, which entails that for every 100 dollars of revenue, it generated $0.14 of operating income.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.620.5518
Moderately Up
Pretty Stable
Net Profit Margin0.150.1427
Sufficiently Up
Very volatile
Operating Profit Margin0.210.1615
Significantly Up
Pretty Stable
Pretax Profit Margin0.210.1661
Significantly Up
Pretty Stable
Return On Assets0.120.0782
Way Up
Very volatile
Return On Equity0.260.1483
Way Up
Very volatile

Abbott Laboratories Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Abbott Laboratories Price Series Summation is a cross summation of Abbott Laboratories price series and its benchmark/peer.

Abbott Laboratories Notable Stakeholders

An Abbott Laboratories stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Abbott Laboratories often face trade-offs trying to please all of them. Abbott Laboratories' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Abbott Laboratories' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Robert FordPresident, Chief Executive Officer, Chief Operating Officer, DirectorProfile
Miles WhiteChairman, CEO and Chairman of Executive CommitteeProfile
Roger BirdSenior Vice President - U.S. NutritionProfile
Heather MasonSenior Vice President - Abbott Diabetes CareProfile
JeanYves PaveeSenior Vice President - Established Pharmaceuticals, Developed MarketsProfile
Stephen FussellExecutive Vice President - Human ResourcesProfile
Thomas FrinziSenior Vice President - Abbott Medical OpticsProfile
Murthy SimhambhatlaSenior Vice President - Abbott Medical OpticsProfile
Michael RousseauPresident - Cardiovascular and NeuromodulationProfile
Hubert AllenExecutive Vice President, General Counsel, SecretaryProfile
Charles FoltzSenior Vice President - Abbott VascularProfile
Brian YoorChief Financial Officer, Executive Vice President - FinanceProfile
Jared WatkinSenior Vice President - Diabetes CareProfile
Scott WhiteSenior Vice President - International NutritionProfile
Deepak NathSenior Vice President - Abbott VascularProfile
Jaime ContrerasSenior Vice President - Core Laboratory Diagnostics, Commercial OperationsProfile
Andrew LaneSenior Vice President - Established Pharmaceuticals, Emerging MarketsProfile
Georges VosSenior Vice President - Established Pharmaceuticals, Emerging MarketsProfile
Eric FainSenior Vice President Group President - Cardiovascular and NeuromodulationProfile
John CapekExecutive Vice President - VenturesProfile
Joseph ManningSenior Vice President - Abbott Nutrition InternationalProfile
Michael WarmuthExecutive Vice President - Established PharmaceuticalsProfile
Robert FunckChief Financial Officer, Executive Vice President - FinanceProfile
Daniel SalvadoriSenior Vice President - Established Pharmaceuticals, Latin America.Profile
Richard AshleyExecutive VP of Corporate Devel.Profile
Brian BlaserExecutive VP of Diagnostic ProductsProfile
Thomas FreymanExecutive VP of Fin. and Admin.Profile
Samuel ScottIndependent DirectorProfile
James FarrellIndependent DirectorProfile
Phebe NovakovicIndependent DirectorProfile
Roxanne AustinIndependent DirectorProfile
Sally BlountIndependent DirectorProfile
Daniel StarksIndependent DirectorProfile
Robert AlpernIndependent DirectorProfile
Glenn TiltonIndependent DirectorProfile
Darren McDewIndependent DirectorProfile
Patricia GonzalezIndependent DirectorProfile
Nancy McKinstryIndependent DirectorProfile
Michelle KumbierIndependent DirectorProfile
Edward LiddyIndependent DirectorProfile
John StrattonIndependent DirectorProfile
William OsbornLead Independent DirectorProfile
Erica BattagliaVP OfficerProfile
Christopher ScogginsSenior Vice President - Rapid DiagnosticsProfile
Michael DaleSenior Vice President - Structural HeartProfile
Sammy KaramSenior Vice President - Established Pharmaceuticals, Emerging MarketsProfile
Michael PedersonSenior Vice President - Electrophysiology and Heart FailureProfile
Lisa EarnhardtExecutive Vice President - Medical DevicesProfile
Alejandro WellischSenior Vice President - Established Pharmaceuticals, Latin AmericaProfile
Christopher CalamariSenior Vice President - U.S. NutritionProfile
Charles BrynelsenSenior Vice President - Abbott VascularProfile
Gregory AhlbergSenior Vice President - Core Laboratory Diagnostics, Commercial OperationsProfile
Philip BoudreauVice President - Finance, ControllerProfile
John GinascolExecutive Vice President - Core DiagnosticsProfile
Michael RomanIndependent DirectorProfile
Mary MorelandExecutive Vice President of Human ResourcesProfile
Sabina EwingSenior OfficerProfile
Randel WoodgriftSenior Vice President - CRMProfile
Elaine LeavenworthVP OfficerProfile
Scott LeinenweberAcquisitions LicensingProfile
James YoungVP OfficerProfile
Louis MorroneSenior Vice President - Rapid DiagnosticsProfile
Andrea WainerExecutive Vice President - Rapid and Molecular DiagnosticsProfile
Melissa BrotzVice MarketingProfile

About Abbott Laboratories Management Performance

The success or failure of an entity such as Abbott Laboratories often depends on how effective the management is. Abbott Laboratories management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Abbott management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Abbott management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.14  0.17 
Return On Capital Employed 0.11  0.10 
Return On Assets 0.08  0.12 
Return On Equity 0.15  0.26 
The data published in Abbott Laboratories' official financial statements usually reflect Abbott Laboratories' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Abbott Laboratories. For example, before you start analyzing numbers published by Abbott accountants, it's critical to develop an understanding of what Abbott Laboratories' liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Abbott Laboratories' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Abbott Laboratories' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Abbott Laboratories' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Abbott Laboratories. Please utilize our Beneish M Score to check the likelihood of Abbott Laboratories' management manipulating its earnings.

Abbott Laboratories Workforce Analysis

Traditionally, organizations such as Abbott Laboratories use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Abbott Laboratories within its industry.

Abbott Laboratories Manpower Efficiency

Return on Abbott Laboratories Manpower

Revenue Per Employee351.8K
Revenue Per Executive626.7M
Net Income Per Employee50K
Net Income Per Executive89.1M
Working Capital Per Employee77.4K
Working Capital Per Executive138M
When determining whether Abbott Laboratories is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Abbott Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Abbott Laboratories Stock. Highlighted below are key reports to facilitate an investment decision about Abbott Laboratories Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy Abbott Stock please use our How to Invest in Abbott Laboratories guide.
Note that the Abbott Laboratories information on this page should be used as a complementary analysis to other Abbott Laboratories' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Abbott Stock analysis

When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Abbott Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abbott Laboratories. If investors know Abbott will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abbott Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.07)
Dividend Share
2.12
Earnings Share
3.21
Revenue Per Share
23.183
Quarterly Revenue Growth
0.022
The market value of Abbott Laboratories is measured differently than its book value, which is the value of Abbott that is recorded on the company's balance sheet. Investors also form their own opinion of Abbott Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Abbott Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abbott Laboratories' market value can be influenced by many factors that don't directly affect Abbott Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abbott Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abbott Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abbott Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.